European Pharmaceutical Review

JULY 5, 2022

In the same statement, Pfizer also announced it has signed a pledge by the US Department of Health and Human Services (HHS) that calls on US healthcare system stakeholders such as hospitals, health systems, payers, suppliers and pharmaceutical companies to reduce GHG emissions and build a more climate resilient healthcare infrastructure.

Pharmaceutical Companies 111

Pharmaceutical Companies Pharmaceutical Companies Hospitals 111

European Pharmaceutical Review

SEPTEMBER 12, 2023

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months.

Drug Development 105

Drug Development Pharmaceutical Companies Pharmaceutical Companies 105

The Guardian - Pharmaceutical Industry

NOVEMBER 12, 2024

The profit figure beat forecasts and the UK pharmaceutical company raised its guidance for growth in full-year revenues and earnings from “mid-teens” to “high teens”. It all sounded like another confident step in the march to take global revenues from $46bn in 2023 to $80bn by 2030. Continue reading.

Pharmaceutical Companies 63

Pharmaceutical Companies Pharmaceutical Companies 63

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. The report noted that there has been “considerable” merger and acquisition activity in recent years within the pharmaceutical contract manufacturing market.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding 52

European Pharmaceutical Review

FEBRUARY 3, 2023

Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies. billion by 2030 The post France gets new sterile liquid drug manufacturing facility appeared first on European Pharmaceutical Review. HPAPI contract manufacturing to value $14.6

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Labelling Diabetes 98

European Pharmaceutical Review

JUNE 10, 2024

The company hopes to produce this number tenfold by the end of 2030. Radioligand therapy developments in 2023 and 2024 Other companies making progress producing radioligand therapies include Novartis. In January 2024, the pharmaceutical company obtained manufacturing authorisation for its largest radioligand therapy facility.

Pharmaceutical Manufacturing 98

Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 98

Express Pharma

MAY 13, 2024

With other pharmaceutical companies entering the race for developing the first marketed therapy against bronchiectasis, the great opportunity in the market is underlined, says GlobalData , a data and analytics company. According to GlobalData’s Sales and Forecast database, brensocatib’s sales are anticipated to reach $1.2

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Labelling 98

Express Pharma

JULY 21, 2024

Recognising the pharmaceutical industry’s substantial contribution to India’s exports, we eagerly anticipate schemes that provide fiscal incentives to encourage such exports. Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030.

Biosimilars 105

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 105

pharmaphorum

JUNE 8, 2021

At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. million in 2030.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

Pharmaceutical Technology

MAY 29, 2023

The global pharmaceutical industry experienced a 17% rise in company filings mentions of blockchain in Q1 2023 compared with the previous quarter, with the highest share accounted for by Bayer, according to GlobalData’s analysis of over 60 pharmaceutical company filings. The overall index for blockchain in Q1 2023 was 74.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 29, 2023

The global pharmaceutical industry experienced a 38% drop in company filings mentions of virtual care in Q1 2023 compared with the previous quarter, with the highest share accounted for by ICON with 25% year-on-year decrease, according to GlobalData’s analysis of over 88 pharmaceutical company filings.

Pharmaceutical Companies 45

Pharmaceutical Companies Pharmaceutical Companies 45

Pharmaceutical Technology

JANUARY 20, 2023

Pharmaceutical companies need to be prepared to answer the call for increased demand and supply into new markets, ensuring the proper resources and logistics framework are in place. In addition, a paper published in 2019, concluded that the pharmaceutical industry produced 48.55

Pharmaceutical Companies 142

Pharmaceutical Companies Pharmaceutical Companies Packaging Communication 142

pharmaphorum

MARCH 10, 2022

“As pipelines shift towards biotechnology, all companies will have to decide between investing in expertise in-house and relying on the pre-existing technological platforms offered by experienced companies.”. The rise of biologics.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunity 98

European Pharmaceutical Review

SEPTEMBER 21, 2023

billion by 2030. Pharmaceutical companies need to work closely with governments and health authorities to find innovative contracting and payment models, such as outcome-based agreements, which consider the clinical and economic value of the treatment to patients, healthcare systems and society.

Drug Development 96

Drug Development Pharmaceutical Companies Pharmaceutical Companies Diabetes 96

PharmaTech

OCTOBER 22, 2023

According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030. This guide serves as a roadmap for pharmaceutical companies, researchers, healthcare professionals, and anyone interested in understanding the fundamentals of decentralized clinical trials.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies 40

Express Pharma

OCTOBER 16, 2024

billion by 2030 (2). Similarly, India’s pharmaceutical contract manufacturing market is expected to increase at a CAGR of 14.67 Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceutical companies. per cent, hitting $44.63

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

pharmaphorum

OCTOBER 17, 2022

. “Novo Nordisk is proud to lead the industry in sustainable business practices, doing our part to give empty pens new purpose,” said the company’s UK general manager, Pinder Sahota. Novo Nordisk is also working towards zero CO2 emissions from operations and transportation by 2030.

Community Pharmacies 64

Community Pharmacies Diabetes Pharmaceutical Companies Pharmaceutical Companies 64

Express Pharma

MARCH 21, 2024

From dissecting market trends to envisioning future in near (2030) and long-term (2047), vriddhi 2024 provided a platform for everyone to engage, collaborate, and chart a course towards sustainable growth. Daara Patel, Secretary General of IDMA, with his chivalrous demeanour was earnest to draw participation from all stakeholders.

Compounding 104

Compounding Pharmaceutical Companies Pharmaceutical Companies 104

pharmaphorum

NOVEMBER 28, 2022

Specifically, the company formed a consortium with other pharmaceutical companies to secure power purchase agreements for their suppliers. In October 2021, Pfizer itself sealed a 15-year virtual power purchase agreement with Vesper Energy that would see the latter company deliver 310 megawatts of renewable energy.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

DECEMBER 21, 2022

“As the contribution of costs of organic chemicals used as feedstock to the operating expenditures is small, the pharmaceutical companies can spearhead and guide the transition.” So, when could the goal of a net zero pharmaceutical industry be achieved?

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

European Pharmaceutical Review

MARCH 7, 2024

Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunity Immunization 52

Pharmaceutical Technology

APRIL 28, 2023

At its Biocon Park campus in Bengaluru the company set up and commissioned a new microbial cGMP facility and expanded its mammalian cell manufacturing facility Meanwhile, Bristol Myers Squibb (BMS), one of the world’s largest pharmaceutical companies, celebrated 25 years of collaboration with Syngene in March 2023.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 15, 2023

Generic and biosimilar pharmaceutical company and Novartis subsidiary Sandoz announced its plan to accelerate patient access to biosimilars. In a 15 June statement, Sandoz said that it hoped the Act4Biosimilars action plan will provide actionable solutions to overcome barriers preventing patient access to biosimilars.

Biosimilars 52

Biosimilars Communication Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

DECEMBER 22, 2022

By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA. The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028. Will the joint procedure drive positive change?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Communication 52

Pharmaceutical Technology

JUNE 8, 2023

AstraZeneca has announced its supply chain will be carbon negative by 2030. Of the world’s 20 largest pharmaceutical companies, 17 have launched programmes tailored towards increasing medication access in low- and middle-income countries – up from just eight in 2010. A similar theme is evident in company filings.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Documentation Communication 52

Fuld & Company Blog

MARCH 27, 2023

billion category in 2022 to $54 billion by 2030. Another question is whether pharmaceutical companies will improve their game by getting approval for an oral version of GLP-1.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

Proxsys Rx

APRIL 4, 2024

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Insurance Coverage and Processing Medication Dispensing 52

Proxsys Rx

AUGUST 22, 2023

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Insurance Coverage and Processing Medication Dispensing 52

European Pharmaceutical Review

MAY 12, 2025

The shift aligns with the pharmaceutical companys Ambition Zero Carbonstrategy, where it is targeting a shift for its wider pMDI portfolio to the near-zero GWP propellant by 2030. Trixeo is the first of AstraZenecas pMDIs to transition to the new propellant.

Pharmaceutical Companies 87

Pharmaceutical Companies Pharmaceutical Companies 87

STAT

DECEMBER 13, 2024

Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Just 9% came from the private sector, such as pharmaceutical companies. Meanwhile, the U.S. Continue to STAT+ to read the full story…

Pharmaceutical Companies 243

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 243

Proxsys Rx

DECEMBER 22, 2023

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Some disease states are projected to experience even higher increases in patient volume.

Specialty Pharmacies 40

Specialty Pharmacies Hospitals Insurance Coverage and Processing Medication Dispensing 40

Express Pharma

MAY 30, 2024

According to GlobalData’s Pharmaceutical Intelligence Center, Eisai’s Aricept has generated $188 million globally in 2023, and Leqembi is expected to become the dominant drug in neurology, with global sales forecasted to rise from $372 million in 2024 to $7.3 billion in 2030, with a compound annual growth rate (CAGR) of 117.6

Compounding 115

Compounding Diabetes Pharmaceutical Companies Pharmaceutical Companies 115

pharmaphorum

JANUARY 24, 2023

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

pharmaphorum

MARCH 31, 2021

Another recent change is the timelier release of scientific information; rather than holding on to clinical trial findings until the ‘perfect’ opportunity to present them at a major congress, 2020 increasingly saw pharmaceutical companies make data public in real time. What are the associated challenges? Conclusion.

Communication 98

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

Express Pharma

JUNE 14, 2024

India’s pharmaceutical industry is a global powerhouse. It is already a massive $50 billion market and is projected to grow to $130 billion by 2030. With a similar rationale, large healthcare buyers (like global pharmaceutical companies, retailers, medical chains, etc.)

Pharmaceutical Companies 110

Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing Packaging 110

Express Pharma

JULY 15, 2024

This would encourage pharmaceutical companies to enhance their R&D efforts, bolstering India’s status as a global leader in innovative healthcare solutions. The government should incentivise research and development (R&D) by increasing the weighted tax deduction for R&D expenditure from 100 per cent to 200 per cent.

Medical Records 105

Medical Records Biosimilars Pharmaceutical Companies Pharmaceutical Companies 105